Our ELISA Kits Travel Worldwide
We are present in over 60 countries, ensuring global availability and customer support through partnerships with selected local distributors on almost every continent. Regardless of your location, we are here to help you reach your goals.
With over 30 years of experience, we specialize in developing and manufacturing high-quality ELISA assay kits for biomarkers in clinical research.
Check out our ELISA Assay product brochure
Our ELISA Kits Travel Worldwide – contact us or your local representative
About us
BIOMEDICA develops and manufactures high quality and widely cited immunoassays for clinical and pre-clinical applications in bone and cardiorenal diseases. For specific biomarkers, Biomedica has become a world-wide leader, e.g. Sclerostin, free sRANKL, OPG, DKK-1, and NT-proCNP.
All Biomedica ELISA assays are fully validated following international quality guidelines. The assays include ready-to-use serum-based calibrators and controls enabling researchers to collect biologically reliable data.
This year’s ELISA assay highlights
Cardiac Safety Biomarkers : Rat NT-proBNP, NT-proANP ELISA kits
FGF23 : FGF23 intact , FGF23 (C-terminal) ELISA kits
Cytokines : VEGF, Angiopoietin-2, IL-6
Discover our PROMOTION : Take 15% OFF of the human IL-6 ELISA Assay now through end of 2024! Making IL-6 ELISA Kits more affordable!
Features & Benefits of BIOMEDICA ELISA Assay Kits
- Highly Specific – many of our kits employ characterized epitope-mapped antibodies
- Excellent Quality – our kits are validated according to international quality guidelines (ICH, FDA..)
- Convenient Use –offering ready to use and color coded reagents – controls are included in all kits!
Other Products
EZ4U – Cell Proliferation & Cytotoxicity Assay (cat. no. BI-5000) for reliable testing of cell viability in 96-well microtiter plates.
Features & Benefits EZ4U Assay
-easy and convenient singe-step incubation for use on living cells
-non-radioactive
-cultivation can be continued after cell numbers are determined
-widely cited in more than 240 publications e.g.
- BRD4-targeting PROTACs Synergize With Chemotherapeutics Against Osteosarcoma Cell Lines
Lang et al., Anticancer Res; 2024; 44 (3), 971-980. PMID: 38423674
- Expression of cytokines in pleural effusions and corresponding cell lines of small cell lung cancer
Rath et al., Transl Lung Cancer Res; 2024; 13 (1), 5-15. PMID: 38405004